Sympathetic block with botulinum toxin to treat complex regional pain syndrome.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 19334078.
- Also identified by DOI 10.1002/ana.21601 and PMC identifier 2763598.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Complex regional pain syndrome is a refractory pain condition with few tested therapies. We hypothesized that botulinum toxin A (BTA) would prolong analgesia after sympathetic blocks in patients with complex regional pain syndrome. We compared the duration of standard lumbar sympathetic block (LSB) with bupivacaine to LSB with bupivacaine and BTA in nine patients with refractory complex regional pain syndrome. Median time to analgesic failure was 71 (95% confidence interval, 12-253) days after LSB with BTA compared with fewer than 10 days (95% confidence interval, 0-12) after standard LSB (log-rank, p < 0.02). BTA profoundly prolonged the analgesia from sympathetic block in this preliminary study.
Medical subject headings
- Botulinum Toxins, Type A
- Complex Regional Pain Syndromes
- Neuromuscular Agents
- Sympathectomy